UnitedHealthcare is placing biosimilar Inflectra on the same preferred formulary tier as the reference brand rheumatoid arthritis biologic Remicade for both United’s commercial and Medicare markets, starting Oct. 1, a United spokesperson confirmed. Remicade maker Johnson & Johnson has blocked uptake of biosimilars, which has sparked lawsuits against the company and an investigation by the Federal Trade Commission . Biosimilars are supposed to lower prices of biologics, but they’ve not worked out as well as planned in part due to...